Dave Gray offers a solid, free Python tutorial that runs for about 9 hours. It’s a pretty methodical course, starting with the basics and moving into more complex stuff like closures and recursion. He ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...

Python has become one of the most popular programming languages out there, particularly for beginners and those new to the hacker/maker world. Unfortunately, while it’s easy to get something up and ...

When applying for a job, your resume is often the first impression an employer gets. A simple resume format is the most professional and widely accepted choice because it is clean, easy to read, and ...

More good reads and Python updates elsewhere Python’s cffi reaches version 2.0 One of the most convenient and popular libraries for calling into the world of C from Python just got a major ...

Millions of pensioners and savers may have received an unexpected tax bill over the summer from HMRC, under the taxman’s simple assessment system. Frozen tax thresholds mean more of people’s earnings ...

The last time I wrote about Recursion Pharmaceuticals (RXRX), it was with respect to a Seeking Alpha article entitled "Recursion: CDK7 Differentiation Is Initially Paying Off." With respect to this ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.03, demonstrating a -1.57% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.22%.